Brokers Set Expectations for Sight Sciences Q1 Earnings

Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) - Equities research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Sight Sciences in a research note issued to investors on Friday, May 9th. William Blair analyst M. Andrew expects that the company will post earnings of ($0.27) per share for the quarter. The consensus estimate for Sight Sciences' current full-year earnings is ($0.99) per share. William Blair also issued estimates for Sight Sciences' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.24) EPS.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. The business had revenue of $17.51 million during the quarter, compared to the consensus estimate of $16.51 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%.

Other analysts have also recently issued research reports about the stock. Piper Sandler cut their price target on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Lake Street Capital raised their price target on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a report on Friday. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. UBS Group reduced their price target on Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research report on Monday, January 27th. Finally, Stifel Nicolaus cut their price objective on Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $3.92.

Sight Sciences Price Performance

NASDAQ:SGHT traded up $0.21 during mid-day trading on Monday, reaching $3.42. The stock had a trading volume of 360,061 shares, compared to its average volume of 213,270. The stock has a 50-day simple moving average of $2.72 and a two-hundred day simple moving average of $3.20. The stock has a market capitalization of $176.80 million, a PE ratio of -3.35 and a beta of 2.41. Sight Sciences has a 12 month low of $2.03 and a 12 month high of $8.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74.

Insider Buying and Selling

In other news, CEO Paul Badawi sold 24,174 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total transaction of $55,600.20. Following the transaction, the chief executive officer now directly owns 6,010,580 shares in the company, valued at $13,824,334. The trade was a 0.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Manohar K. Raheja purchased 10,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were purchased at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the purchase, the executive vice president now directly owns 145,000 shares of the company's stock, valued at $395,850. This represents a 7.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 35,196 shares of company stock worth $81,001 in the last 90 days. Insiders own 30.90% of the company's stock.

Hedge Funds Weigh In On Sight Sciences

Large investors have recently modified their holdings of the business. ProShare Advisors LLC acquired a new stake in Sight Sciences during the 4th quarter valued at $36,000. Dynamic Technology Lab Private Ltd bought a new stake in Sight Sciences in the fourth quarter valued at about $40,000. Arkadios Wealth Advisors acquired a new position in Sight Sciences in the fourth quarter valued at approximately $47,000. WealthTrust Asset Management LLC acquired a new position in shares of Sight Sciences during the fourth quarter worth approximately $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Sight Sciences in the fourth quarter worth approximately $50,000. 55.51% of the stock is owned by hedge funds and other institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.